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Abstract
Background: For its low cost and ease of handling, the mouse remains the preferred experimental animal
for preclinical tests. To avoid the interaction of the animal immune system, in vivo antibiotic
pharmacodynamic studies often employ cyclophosphamide (CPM) to induce neutropenia. Although high
doses (350–450 mg/kg) are still used and their effects on mouse leukocytes have been described, a lower
dose (250 mg/kg) is widely preferred today, but the characteristics and applicability of this approach in
outbred mice have not been determined.
Methods: Fifteen female ICR mice were injected intraperitoneally with 150 and 100 mg/kg of CPM on
days 1 and 4, respectively. Blood samples (~160 µL) were drawn from the retro-orbital sinus of each
mouse on days 1, 4, 5, 6, 7 and 11. Leukocytes were counted manually and the number of granulocytes
was based on microscopic examination of Wright-stained smears. The impact of neutropenia induced by
this method was then determined with a variety of pathogens in three different murine models of human
infections: pneumonia (Klebsiella pneumoniae,  Streptococcus pneumoniae,  Staphylococcus aureus),
meningoencephalitis (S. pneumoniae), and the thigh model (S. aureus, Escherichia coli, Bacteroides fragilis).
Results: The basal count of leukocytes was within the normal range for outbred mice. On day 4, there
was an 84% reduction in total white blood cells, and by day 5 the leukopenia reached its nadir (370 ± 84
cells/mm3). Profound neutropenia (≤10 neutrophils/mm3) was demonstrated at day 4 and persisted
through days 5 and 6. Lymphocytes and monocytes had a 92% and 96% decline between days 1 and 5,
respectively. Leukocytes recovered completely by day 11. Mice immunosupressed under this protocol
displayed clinical and microbiological patterns of progressive and lethal infectious diseases after inoculation
in different organs with diverse human pathogens.
Conclusion: A CPM total dose of 250 mg/kg is sufficient to induce profound and sustained neutropenia
(<10 neutrophils/mm3) at least during 3 days in outbred mice, is simpler than previously described
methods, and allows successful induction of infection in a variety of experimental models.
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Background
Currently, animal models of infection are considered
essential for the study of physiopathology and pharma-
cology of infectious disease, being the best tool to bridge
in vitro studies and clinical trials [1]. The neutropenic
mouse thigh infection model has been extensively used,
and its impact on the current knowledge of antimicrobial
pharmacology is undisputable [2]. It allowed the quanti-
tative determination of pharmacokinetic (PK) and phar-
macodynamic (PD) indices (PK/PD) useful to predict
antibiotic efficacy while minimizing selection of resistant
mutants [2]. This revolutionary advance in pharmacology
was reached after characterizing the complex relationship
between host, drug and pathogen, thanks to the unique
opportunity offered by animal models for comparing the
responses to infection and therapy under several immune
statuses [3].
Antibiotic activity can be positively influenced by the host
immune system. For instance, the magnitude of the PK/
PD index necessary for successful therapy is reduced in
animal models by the presence of neutrophils [3,4]. Thus,
in order to study in vivo the intrinsic activity of antibiotics
without the influence of the immune system, animals are
commonly rendered neutropenic with cytotoxic agents
like 5-fluorouracil, methotrexate, and cyclophosphamide
(CPM). In fact, the latter is the most frequently used
immunosuppressive agent in experimental anti-infective
pharmacology. CPM is a prodrug requiring metabolic
transformation to generate active alkylating species. The
initial activation is mediated by hepatic cytochrome P-
450 enzymes and is the major pathway of elimination of
the parent drug. Hydroxylation at the carbon-4 position
of the oxazaphosphorine ring produces 4-hydroxycyclo-
phosphamide in equilibrium with the tautomer aldo-
phosphamide, which spontaneously degrades to
phosphoramide mustard and acrolein [5]. These alkylat-
ing species bind to DNA and induce strand breakage and
cross-linking, killing actively replicating cells [6].
Although the effects in mice of high doses of CPM (350–
450 mg/kg) have already been described [7] and some
authors still use them [8-10], a lower dose (250 mg/kg) is
preferred nowadays [11-13]. The low dose regimen is
derived from a rat model [14,15], but the length and
extent of the induced neutropenia in outbred mice have
not been characterized in detail [16]. At the same time,
outbred mice are preferred for infection models because
their genetic diversity allows determination of individual
responses to infection and treatment. Such individuality
constitutes another reason to study their response to the
method of immunosupression.
The aim of this study was to evaluate the efficacy of a sim-
plified 250 mg/kg regimen of CPM for murine immuno-
supression, characterizing its effects on white blood cells,
including neutrophils, lymphocytes and monocytes, and
its impact in three different animal models of infection
with a variety of human pathogens.
Methods
Mice
For all experiments we used 6 week-old, female, murine
pathogen free Swiss albino mice, belonging to the strain
Udea:ICR(CD-1), and weighting 23–27 g [17]. All mice
received sterile food and water ad libitum and were
housed individually during the experiments. The study
was approved by the University of Antioquia Animal Care
and Experimentation Committee.
Cyclophosphamide treatment
CPM powder (Cytoxan®, Bristol Myers Squibb, NY, USA)
was dissolved in distilled USP water for injection to a final
concentration of 20 mg/mL. Fifteen animals were sub-
jected to CPM treatment in order to have 10 mice for daily
bleeding and 5 reserved to replace any dead animal. All
mice received a total dose of 250 mg/kg by two 0.5 mL
intraperitoneal injections scheduled at day 1 (150 mg/kg)
and day 4 (100 mg/kg).
Blood leukocytes counts
Blood samples (~160 µL) were taken from the retro-
orbital plexus in heparinized capillary tubes (Modulohm
A/S, Herlev, Denmark) at 9:00 AM on days 1, 4, 5, 6, 7 and
11. Total and differential white blood cell counts (neu-
trophils, lymphocytes and monocytes) were performed
manually for each sample using a Neubauer chamber
(Brand GMBH, Wertheim, Germany) and microscopic
examination of Wright-stained smears with 100X objec-
tive [18].
Animal models of infection
Neutropenic mouse thigh infection model
we tested the applicability of this immunosupression
method inducing sepsis with three different pathogens
and using the number of microorganisms growing in the
thighs as the end-point. For the thigh model, all mice were
infected on day 5 of immunosupression, 16 hours after
the second dose of CPM.
First, to determine bacterial growth along time in the tis-
sues of neutropenic mice with and without antibiotic
treatment, we designed an in vivo time-kill curve experi-
ment with this model. The thighs of 36 anaesthetized
mice were inoculated with a 100 µL suspension contain-
ing 104–5 colony forming units per milliliter (CFU/mL) of
log-phased Staphylococcus aureus GRP-0057, a wild-type
clinical isolate. Four untreated mice were sacrificed at the
time of infection and when treatment started two hours
later. The remaining 32 animals were randomized (16BMC Infectious Diseases 2006, 6:55 http://www.biomedcentral.com/1471-2334/6/55
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mice each group) to treatment with sterile saline or vanco-
mycin (Vancocin®CP, Ely Lilly & Co., Mexico, D.F.), 1200
mg/kg/day administered by subcutaneous injections
divided every 3 hours. Two animals from each group were
sacrificed at 3, 6, 9, 12, 15, 18, 21, and 24 hours after start-
ing treatment, and their thighs dissected, homogenized,
and properly diluted for agar plating, incubation, and col-
ony counting (CFU/g).
Second, we determined the size of the inoculum needed
to successfully induce disease with E. coli SIG-1, a clinical
isolate resistant to ampicillin, ampicillin-sulbactam, and
first-generation cephalosporins. Groups of 6 neutropenic
mice were inoculated in the thighs with 2, 3, 4, 5, and 6
logs of bacteria, and 2 animals from each inoculum group
were killed immediately after infection (hour 0) and 2
and 26 hours later. The experiment for the group inocu-
lated with 4 logs was repeated in a different time with
another group of 6 mice to test for reproducibility. The
thighs were harvested as described above.
Third, we infected the mice with B. fragilis ATCC 25285
(8.0 log10 CFU/mL) mixed with E. coli SIG-1 (6.0 log10
CFU/mL) to measure the extent to which bacterial syner-
gism could be achieved in neutropenic animals. Of note,
anaerobes do not grow in the thighs of neutropenic out-
bred mice without a second, usually aerobe pathogen. Six-
teen neutropenic mice were inoculated in the thighs to
determine the number of viable B. fragilis cells right after
infection (hour 0) and at 2, 4, 6, 12, 18, 23, and 26 hours
(2 mice per time-point). Except for the anaerobic tech-
niques required to handle and culture B. fragilis, thigh har-
vesting followed the routine described above.
Pneumonia models
we inoculated neutropenic mice with aerosolized Kleb-
siella pneumoniae GRP-0107 (a wild-type clinical isolate)
and with nasal instillation of Streptococcus pneumoniae
INS-E611 (a penicillin-resistant strain obtained from a
patient with meningitis) or Staphylococcus aureus ATCC
29213. For the first model, we exposed 10 mice during 45
minutes to bacterial aerosols produced by a Collison neb-
ulizer from a log-phased suspension with ~109 CFU/mL,
starting 24 hours after the second dose of CPM (day 5).
Two animals were sacrificed randomly at the time of infec-
tion and 14, 28, 34 and 38 hours later. For the second
model, ten neutropenic and deeply anesthetized mice
were instilled 50 µL log-phased bacterial suspension by
the nasal route 16 hours after the second dose of CPM
(day 5). Two mice were sacrificed at the time of infection
and 6, 14, 24 and 38 hours later. The lungs were harvested
and properly diluted and plated, in a similar manner as
described for the thigh model.
Meningoencephalitis model
to determine the impact of severe neutropenia induced by
this protocol on the reproducibility of an experimental
infection, we modified a model of acute meningoen-
cephalitis [19] and compared bacterial growth in mice
with severe neutropenia (CPM group) and normal leuko-
cyte counts (control group). We chose this model because
the method for bacterial inoculation allows induction of
successful infection even in normal mice. Animals from
CPM and control groups (52 and 45 animals, respec-
tively) were inoculated directly into the frontal lobe by
supra-retro orbital injection of 50 µL bacterial suspension
containing 105–6 CFU/mL of S. pneumoniae GRP-0056, a
trimethoprim-sulfamethoxazole resistant clinical isolate.
At least two animals were killed at the time of infection
and every 1 hour during five hours afterwards (CPM
group), and then every 6 hours (both groups) during 36
hours. Brains were harvested and plated in a similar fash-
ion as described for the thigh model, accounting for
proper dilutions to express data as CFU/g.
Results
General aspects
Ten mice were bled as scheduled up to days 5 and 6, when
2 and 3 animals respectively had to be replaced. The rea-
son to replace these 5 animals was clinical deterioration
Table 1: Leukocytes counts of female Udea:ICR(CD-1) mice at baseline and after treatment with a low-dose cyclophosphamide 
regimen. Total number of leukocytes (cells/mm3) and differential count in peripheral blood of 10 mice at baseline in day 1 (8 hours 
prior to first dose), at day 4 (8 hours prior to second dose), during immunosupression (days 5–7), and at recovery (day 11), compared 
with reference values for 6 week-old mice.
White blood-cell 
Population
Cells/mm3 (± SEM) Normal 
Range
D a y  1D a y  4D a y  5D a y  6D a y  7 D a y  1 1
Total 
Leukocytes
5155 (405) 845 (104) 370 (84) 610 (94) 620 (179) 5863 (1103) 1000–5000
Neutrophils 528 (50) 0 (0) 10 (10) 0 (0) 36 (31) 1700 (321) 110–2150
Lymphocytes 4256 (395) 831 (100) 337 (72) 517 (95) 419 (124) 2905 (415) 500–4300
Monocytes 371 (74) 14 (7) 14 (9) 93 (29) 166 (76) 1248 (604) 10–300BMC Infectious Diseases 2006, 6:55 http://www.biomedcentral.com/1471-2334/6/55
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due to blood loss. On day 11, one animal had systemic
signs of infection and was excluded from the last bleeding
point.
Verification of leukopenia
The basal count of leukocytes was determined at day 1, 8
hours before the first dose of CPM (150 mg/kg). Total and
differential white blood cells counts were within the nor-
mal range for outbred mice [20]. On day 4, 8 hours before
the second injection of CPM (100 mg/kg), there was an
84% reduction in total white blood cells. Leukopenia
reached the nadir at day 5 (370 ± 84/mm3), 16 hours after
the second dose of CPM. This is particularly important for
the thigh infection model, because the procedure for bac-
terial inoculation takes place on the fifth day at this time
(9:00 AM). Leukocytes began to recover at day 6 and
reached normal values by day 11 (Table 1).
Neutrophils, lymphocytes and monocytes
The initial number of neutrophils in normal mice was 528
± 50 cells/mm3. Figure 1 illustrates how CPM 250 mg/kg
induced severe neutropenia (≤10 neutrophils/mm3) by
day 4 and the absolute neutrophils count remained below
this value throughout days 5 and 6 for all animals. By day
7, mice had 36 ± 31 neutrophils/mm3, and at day 11 they
all had returned gradually to normal but greater than
baseline values (1700 ± 321 cells/mm3). Lymphocyte and
monocyte counts declined 92% and 96% by day 1 and 5,
respectively, and started to recover after day 7.
Animal models of infection
Figure 2 shows in vivo growth curves of S. aureus GRP-
0057 in neutropenic mice, and response to treatment with
vancomycin under the thigh infection model. Bacteria dis-
played a constant rate of growth with minimal variance
Length and extent of neutropenia induced in female ICR mice after a low-dose cyclophosphamide regimen Figure 1
Length and extent of neutropenia induced in female ICR mice after a low-dose cyclophosphamide regimen. Total number of 
neutrophils in peripheral blood of 10 mice along 11 days after 2 intraperitoneal injections of cyclophosphamide. Data-points 
represent means ± standard error of the mean.BMC Infectious Diseases 2006, 6:55 http://www.biomedcentral.com/1471-2334/6/55
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that provides reliable data for antibiotic efficacy with this
model, allowing the use of only two animals per dose and
reducing untreated controls to the time of starting (2
mice) and ending (2 mice) therapy. Neutropenia also
allowed for reproducible induction of infection inde-
pendently of the inoculum size, as demonstrated by the
experiments with E. coli SIG-1 (Figure 3). The model of
anaerobic synergistic infection was also successful and
reproducible, even with the desirable intra and inter-indi-
vidual variation characteristic of outbred mice (Figure 4).
Lethality for these models approximates 100% 48 hours
after infection (data not shown).
Lung infection models are difficult to reproduce, particu-
larly with penicillin-resistant S. pneumoniae (PRSP).
However, we found that neutropenic mice develop pro-
gressive pneumonia with all pathogens used (Figure 5)
without recurring to nonphysiologic or traumatic meth-
ods for inoculation. Pneumonia was uniformly lethal 72
hours after infection with K. pneumoniae and S. aureus,
but most PRSP infected mice had recovered their health
by day 11, when neutrophil values had returned to nor-
mal (data not shown).
Meningoencephalitis was easily induced to immunocom-
petent mice, allowing us to compare bacterial growth var-
iance in the brain of animals treated with the low-dose
CPM regimen against that of normal mice (Figure 6). Fit-
ted to a polynomial cubic equation, the growth curves of
S. pneumoniae GRP-0056 in the brains of neutropenic and
In vivo efficacy of vancomycin 1200 mg/kg/day (red squares) compared with sterile saline (black squares) against S. aureus GRP- 0057 in the neutropenic mouse thigh infection model Figure 2
In vivo efficacy of vancomycin 1200 mg/kg/day (red squares) compared with sterile saline (black squares) against S. aureus GRP-
0057 in the neutropenic mouse thigh infection model. Immunosupression achieved with a low-dose (250 mg/kg) cyclophospha-
mide regimen; treatment administrated every 3 hours by subcutaneous injections. Each data-point represents the mean ± 
standard deviation from both thighs of 2–4 mice (unseen error bars are contained within symbols).BMC Infectious Diseases 2006, 6:55 http://www.biomedcentral.com/1471-2334/6/55
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normal mice favored the first group with smaller variation
(standard error of the estimate, 0.3522 and 0.8194,
respectively) and greater correlation between dependent
(growth) and independent (time) variables (adjusted R2,
0.9618 and 0.7876, respectively).
Discussion
The results of this study provide the first comprehensive
characterization of the effects of a commonly used, low-
dose CPM regimen on peripheral blood leukocytes in
female outbred mice. It allowed successful and reproduc-
ible induction of diverse models of infectious diseases,
independently of the method of inoculation, the patho-
gen used, or its susceptibility pattern.
CPM, a chemotherapeutic agent, has several effects that
can impair host resistance, but the decrease in the number
of circulating granulocytes is probably one of the most
important factors for its use in different animal models,
because it promotes severe infection (e.g. sepsis) and
allows close quantification of the intrinsic efficacy of anti-
biotics. Previous research on animal infection models
using irradiated mice showed that bacterial growth is
inversely related to the number of granulocytes in periph-
eral blood [21,22], and other authors demonstrated with
the thigh infection model that there was a significant dif-
ference in CFU numbers at the site of infection between
mice treated with CPM (250 mg/kg) and non-neutropenic
mice [23].
Previous works have also shown that, after profound neu-
tropenia, mice recovered from CPM immunosupression
with an increment in the number of blood leukocytes [24-
26]. We observed a similar phenomenon at day 11 when
Impact of the inoculum size in bacterial growth using the neutropenic mouse thigh infection model with E. coli SIG-1 Figure 3
Impact of the inoculum size in bacterial growth using the neutropenic mouse thigh infection model with E. coli SIG-1. A low-
dose cyclophosphamide regimen allowed successful induction of systemic infection inoculating as little as 100 microorganisms 
per thigh. Each data-point represents one thigh (2–4 mice per time-point), with the growth curve passing through the mean ± 
standard deviation.BMC Infectious Diseases 2006, 6:55 http://www.biomedcentral.com/1471-2334/6/55
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all mice, previously neutropenic, displayed relative neu-
trophilia compared with baseline values (Table 1 and Fig-
ure 1). It is important to bear this fact in mind when
designing or modifying the duration of the experimental
model, particularly when using survival as the end-point.
The low-dose CPM regimen is best suited for animal mod-
els equal to or shorter than 4 days after infection, inde-
pendent of the selected endpoint (number of remaining
microorganisms or animal survival). Models longer than
5 days would have both of these endpoints affected by the
incipient recovery of the immune system. If such a model
was necessary, a third dose of CPM might be required.
Severe neutropenia is not necessarily defined by the same
value in humans and mice. The lower limit of neutrophil
count in the normal mouse is 110 cells/mm3 [20], while
for normal humans it is 1800 cells/mm3 [27]. Although
100 neutrophils (5.56% of 1800) imply severe neutrope-
nia for a patient, the same value is still very close to nor-
mal for the mouse (90.9% of 110). Based on this
comparison, we preferred to use 10 neutrophils/mm3
(9.1% of 110) to define severe neutropenia for the mouse.
We found that the first cell line affected by the low-dose
CPM regimen was the granulocytic followed by the lym-
phocytic line. While neutropenia is obtained with the first
dose (150 mg/kg), the second dose (100 mg/kg) must be
administered to have lymphopenic mice. On the other
hand, monocyte counts were reduced 96% by day 5 with
our low-dose intraperitoneal CPM regimen, but the abso-
lute cell number did not reach the inferior normal limit
for the mouse (10 cells/mm3). This is not surprising, since
Growth curve of B. fragilis ATCC 25285 in the thighs of mice rendered neutropenic under a low-dose cyclophosphamide pro- tocol Figure 4
Growth curve of B. fragilis ATCC 25285 in the thighs of mice rendered neutropenic under a low-dose cyclophosphamide pro-
tocol. This model took advantage of bacterial synergism by inoculating the animals with a mixed culture (+ E. coli SIG-1; not 
shown in this graph). Empty black circles represent one thigh (2 mice per time-point); filled blue circles and lines are means ± 
standard deviations.BMC Infectious Diseases 2006, 6:55 http://www.biomedcentral.com/1471-2334/6/55
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a previous work already showed that monocytopenia was
induced only when the drug was administered by the sub-
cutaneous route [7].
The use of various animals as models for microbiological
infections has been a fundamental part of infectious dis-
ease research for more than a century. The data from ani-
mal models provide means for screening potential
treatments and eliminating undesirable ones, narrowing
the successful candidates for use in human studies. Due to
the ease of handling and reproducibility, the neutropenic
murine thigh infection model has been extensively used,
especially to evaluate the relationship between host, drug
and microorganism in the absence of immunity, which
often acts as a confounding variable [16,28-30]. While
inbred and outbred stocks have been employed for this
model, the latter are preferred in pharmacology and toxi-
cology studies because they represent better the genetic
variability observed in human populations. Although
there is a brief description of the neutropenia process after
injecting low-dose CPM to inbred mice [14,31], the
response of outbred mice had not been thoroughly
described, and some authors feel more comfortable using
the high-dose regimen [8-10]. The high-dose regimen
requires greater CPM concentration per injection (250
mg/kg) or more than two injections, conditions implying
unnecessary exposure of researchers and environment to
this expensive carcinogenic agent [32,33], as well as
Comparison of bacterial growth of three human pathogens in the lungs of neutropenic mice inoculated by nasal instillation of S.  aureus ATCC 29213 and S. pneumoniae INS-E611 or aerosolized K. pneumoniae GRP-0107 Figure 5
Comparison of bacterial growth of three human pathogens in the lungs of neutropenic mice inoculated by nasal instillation of S. 
aureus ATCC 29213 and S. pneumoniae INS-E611 or aerosolized K. pneumoniae GRP-0107. The apparent difference in the 
extension of the growth curves is due to the fact that mice infected with pneumococci survived the model, while the other 
organisms killed the animals 24–48 hours after infection; other details for each model in the text.BMC Infectious Diseases 2006, 6:55 http://www.biomedcentral.com/1471-2334/6/55
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greater risk of deadly peritoneal trauma and hemorrhagic
cystitis for the animals [34].
Our results demonstrate that a low-dose CPM regimen
induces severe neutropenia (≤10 cell/mm3) in outbred
mice, sustained enough to reliably execute animal models
of infection with different endpoints up to 4 days long.
Two doses simplify drug administration, and minimize
the aforementioned problems associated with high-dose
CPM, without compromising the model performance.
Conclusion
Previous results from a variety of papers suggest that intra-
peritoneal injections of CPM, administered 4 days (150)
and 1 day (100 mg/kg) before experimental infection,
induce neutropenia (≤100 neutrophils/mm3) in inbred
mice and rats. Here, we showed that this low-dose regi-
men also induces profound and sustained neutropenia
(<10 neutrophils/mm3) in outbred mice lasting at least 3
days. The use of a lower dose of CPM divided in two intra-
peritoneal injections is simpler, safer, and very effective to
attain reproducible animal models of infection.
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Influence of severe neutropenia (<10 cells/mm3) in the growth curves variance of S. pneumoniae GRP-0056 in a murine model  of acute meningoencephalitis Figure 6
Influence of severe neutropenia (<10 cells/mm3) in the growth curves variance of S. pneumoniae GRP-0056 in a murine model 
of acute meningoencephalitis. Besides the brain (shown here), variance in mice survival and bacterial numbers in other organs 
(cerebellum, cerebrospinal fluid) is also smaller for neutropenic mice (black circles) compared with immunocompetent animals 
(red squares). Data-points represent means ± standard deviations from 2–10 mice.BMC Infectious Diseases 2006, 6:55 http://www.biomedcentral.com/1471-2334/6/55
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